Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | £1,829,812 | £1,680,570 | £0 | £1,364,518 |
| Dep. & Amort. | £0 | £0 | £0 | -£984,895 |
| Deferred Tax | £0 | £0 | £0 | £0 |
| Stock-Based Comp. | £0 | £0 | £0 | £0 |
| Change in WC | -£789,413 | £0 | £809,242 | £743,325 |
| Other Non-Cash | -£2,767 | £16,549 | £956,506 | £1,008,078 |
| Operating Cash Flow | £1,037,632 | £1,697,119 | £1,765,748 | £2,131,026 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -£1,216,059 | -£310,588 | -£620,942 | -£389,159 |
| Net Acquisitions | £0 | £0 | £0 | £0 |
| Inv. Purchases | £0 | £0 | £0 | £0 |
| Inv. Sales/Matur. | £0 | £0 | £0 | £0 |
| Other Inv. Act. | -£341,674 | -£265,476 | -£33,858 | £44,790 |
| Investing Cash Flow | -£1,557,733 | -£576,064 | -£654,800 | -£344,369 |
| Financing Activities | – | – | – | – |
| Debt Repay. | £1,324,054 | -£1,122,470 | -£1,411,899 | -£196,108 |
| Stock Issued | £0 | £0 | £0 | £0 |
| Stock Repurch. | £0 | £0 | £0 | £0 |
| Dividends Paid | -£44 | -£1,293 | -£17,696 | -£1,567,078 |
| Other Fin. Act. | £0 | £0 | £0 | £41,122 |
| Financing Cash Flow | £1,324,010 | -£1,123,763 | -£1,429,595 | -£1,722,064 |
| Forex Effect | -£8,002 | £7,967 | £12,327 | £18 |
| Net Chg. in Cash | £795,907 | £5,259 | -£306,318 | £64,611 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | £859,365 | £854,106 | £1,160,424 | £1,095,813 |
| End Cash | £1,655,272 | £859,365 | £854,106 | £1,160,424 |
| Free Cash Flow | -£279,866 | £1,386,531 | £1,144,807 | £1,715,209 |